Cassava Sciences (SAVA) Scheduled to Post Quarterly Earnings on Thursday

Cassava Sciences (NASDAQ:SAVA) will be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.37) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Cassava Sciences (NASDAQ:SAVA) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.57. During the same period in the prior year, the firm posted ($0.63) earnings per share. On average, analysts expect Cassava Sciences to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cassava Sciences Stock Down 4.9 %

NASDAQ:SAVA traded down $1.26 during mid-day trading on Tuesday, reaching $24.58. The company’s stock had a trading volume of 921,480 shares, compared to its average volume of 1,702,940. The stock has a fifty day moving average of $27.92 and a 200-day moving average of $22.89. Cassava Sciences has a 1 year low of $8.79 and a 1 year high of $42.20.

Analyst Ratings Changes

Several equities analysts recently issued reports on SAVA shares. HC Wainwright raised shares of Cassava Sciences from a “neutral” rating to a “buy” rating and set a $116.00 price objective on the stock in a report on Tuesday, October 8th. Rodman & Renshaw reissued a “buy” rating and issued a $107.00 price target on shares of Cassava Sciences in a research report on Thursday, August 8th.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.